SCHEMBL23216720

SCHEMBL23216720

COc1cc(C(F)(F)CCC(=O)O)ccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.48
SLC13A5 Q86YT5 1/20 0.44
SORT1 Q99523 1/20 0.44
LOX P28300 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
SYK P43405 2/20 0.37
CTSA P10619 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
RORC P51449 1/20 0.36
ALDH1A1 P00352 2/20 0.36
ESR1 P03372 1/20 0.36
CYP3A4 P08684 1/20 0.36
ESR2 Q92731 1/20 0.36
HDAC4 P56524 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
NR2E1 Q9Y466 1/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29664623 1.00 FFAR1 (0.48) FFAR1SLC13A5SORT1LOXLOXL2
SCHEMBL23215037 0.93 FFAR1 (0.45) FFAR1SLC13A5SORT1LOXLOXL2
SCHEMBL29664732 0.93 FFAR1 (0.45) FFAR1SLC13A5SORT1LOXLOXL2
SCHEMBL23216919 0.84 SORT1 (0.38) FFAR1SLC13A5SORT1LOXLOXL2
SCHEMBL29664670 0.81 LOX (0.41) FFAR1SLC13A5SORT1LOXLOXL2
SCHEMBL23215087 0.81 LOX (0.41) FFAR1SLC13A5SORT1LOXLOXL2
SCHEMBL29664692 0.80 LOX (0.45) FFAR1SLC13A5SORT1LOXLOXL2
SCHEMBL23215152 0.80 LOX (0.45) FFAR1SLC13A5SORT1LOXLOXL2
SCHEMBL24094523 0.78 SORT1 (0.46) FFAR1SLC13A5SORT1LOXLOXL2
SCHEMBL30341084 0.78 SORT1 (0.46) FFAR1SLC13A5SORT1LOXLOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2026-05-21 US disclosed
US-12565501-B2 Muscarinic acetylcholine M1 receptor antagonists CONTINEUM THERAPEUTICS, INC. (US) 2026-03-03 US disclosed
US-20250171455-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2025-05-29 US disclosed
US-20240217981-A1 CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS, INC. 2024-07-04 US disclosed
US-20240217981-A1 CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS, INC. 2024-07-04 US disclosed
EP-4322951-A1 CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS Pipeline Therapeutics, Inc. (US) 2024-02-21 EP disclosed
CN-117479941-A Crystalline compounds of muscarinic acetylcholine M1 receptor antagonists 帕珀莱恩医疗公司 2024-01-30 CN disclosed
US-20230089921-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS, INC. 2023-03-23 US disclosed
WO-2022221450-A1 CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS Pipeline Therapeutics, Inc. (US) 2022-10-20 WO disclosed
CN-114729044-A Muscarinic acetylcholine M1Receptor antagonists 帕珀莱恩医疗公司 2022-07-08 CN disclosed
WO-2021071843-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS Pipeline Therapeutics, Inc. (US) 2021-04-15 WO disclosed
WO-2021071843-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS Pipeline Therapeutics, Inc. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12565501-B2 Muscarinic acetylcholine M1 receptor antagonists CHRM1, CHRM2, CHRM3 FFAR1 172/4885SLC13A5 1518/4885SORT1 4083/4885
US-20230089921-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM3 FFAR1 243/4885SLC13A5 2745/4885SORT1 1914/4885
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM5, CHRM3 FFAR1 135/4885SLC13A5 993/4885SORT1 3335/4885
US-20240217981-A1 CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM3 FFAR1 79/4885SLC13A5 2363/4885SORT1 1612/4885
US-20250171455-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM3 FFAR1 244/4885SLC13A5 2714/4885SORT1 1924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.